ArticleTranslational oncology2010

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals.

Terence O'Reilly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.